Brazikumab - Misplaced Pages

Pharmaceutical drug Pharmaceutical compound

Brazikumab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	IL23
Clinical data
Other names	MEDI2070
ATC code	none
Identifiers
CAS Number	1610353-18-8
ChemSpider	none
UNII	50EI9G8Q6U
KEGG	D10912
Chemical and physical data
Formula	C₆₄₁₀H₉₈₃₀N₁₇₁₈O₂₀₁₆S₅₀
Molar mass	144820.16 g·mol

Brazikumab (INN; development code MEDI2070) is a human monoclonal antibody designed for the treatment of Crohn's disease. that targets IL-23.

This drug was developed by MedImmune.

References

Statement On A Nonproprietary Name Adopted By The USAN Council - Brazikumab, American Medical Association
World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 115" (PDF). WHO Drug Information. 30 (2).
Hanžel J, D'Haens GR (April 2020). "Anti-interleukin-23 agents for the treatment of ulcerative colitis". Expert Opinion on Biological Therapy. 20 (4): 399–406. doi:10.1080/14712598.2020.1697227. PMID 31760827.

Monoclonal antibodies for the immune system

Immune system

Human	Immunosuppression: Abrilumab Adalimumab Anifrolumab Atorolimumab Avelumab Avdoralimab Belimumab Bleselumab Brodalumab Camidanlumab tesirine Carlumab Cemiplimab Dupilumab Eldelumab Emapalumab Fresolimumab Golimumab Ianalumab Lanadelumab Lenzilumab Lerdelimumab Lirentelimab Lirilumab Mavrilimumab Metelimumab Morolimumab Namilumab Oleclumab Oxelumab§ Pamrevlumab Placulumab Relatlimab Sarilumab Sifalimumab Tabalumab Tezepelumab Ulocuplumab Varlilumab Immune activation: Ipilimumab Durvalumab Nivolumab Tremelimumab Urelumab Other: Bertilimumab Ontamalimab Zanolimumab Combination: Nivolumab/relatlimab
Mouse	Afelimomab Elsilimomab Faralimomab Gavilimomab Inolimomab Maslimomab Nerelimomab Odulimomab Telimomab aritox Vepalimomab Zolimomab aritox
Chimeric	Andecaliximab Basiliximab Clenoliximab Galiximab Gomiliximab Infliximab Keliximab Lumiliximab Priliximab Teneliximab Vapaliximab
Humanized	Immunosuppressive: Apolizumab Aselizumab Atezolizumab Benralizumab Camrelizumab Cedelizumab Certolizumab pegol Crizanlizumab Daclizumab Eculizumab Efalizumab Epratuzumab Erlizumab Etrolizumab Fontolizumab Frexalimab Inebilizumab Itolizumab Lampalizumab Letolizumab Ligelizumab Lulizumab pegol Mepolizumab Mogamulizumab Natalizumab Ocrelizumab (+hyaluronidase) Omalizumab Ozoralizumab Pascolizumab Pateclizumab Pembrolizumab Pexelizumab Pidilizumab Plozalizumab PRO 140 Quilizumab Ravulizumab Reslizumab Retifanlimab Rontalizumab Rovelizumab Ruplizumab Samalizumab Satralizumab Siplizumab Spartalizumab Talizumab Teclistamab Teplizumab Tislelizumab Tocilizumab Toralizumab Tregalizumab Vatelizumab Vedolizumab Visilizumab Vobarilizumab TGN1412 Immune activation: Dostarlimab Other: Ibalizumab
Chimeric + humanized	Otelixizumab Rozanolixizumab Sutimlimab

Interleukin

Human	Bermekimab Brazikumab Briakinumab Canakinumab Fezakinumab Fletikumab Guselkumab Secukinumab Sirukumab Tralokinumab Ustekinumab
Humanized	Anrukinzumab Bimekizumab Clazakizumab Gevokizumab Ixekizumab Mirikizumab Lebrikizumab Olokizumab Perakizumab Risankizumab Spesolimab Tildrakizumab
Veterinary	Lokivetmab

Inflammatory lesions

Mouse	Besilesomab Fanolesomab Lemalesomab Sulesomab

WHO-EM
Withdrawn from market
Clinical trials:
- Phase III
- Never to phase III

This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it.

Categories: